Connect with us

Press Release

Bow Miner: The best free Bitcoin cloud mining platform in 2025, helping you earn daily passive income

Published

6 months ago

on

Bow Miner is the world’s leading cloud mining platform with a clear mission: to provide the tools and services you need to succeed in the digital asset space. Committed to empowering the future of finance with clean energy and providing the high-performance equipment required to achieve maximum computing power

Bow Miner works in harmony with 6.3 million smart cloud computing investors. Founded in 2018, Bow Miner adheres to the concept of “long-term investment and asset allocation”, starting from clean energy, and has now developed into an online cloud computing service platform with impact investment. Bow Miner currently has top blockchain technology talents, bringing together people from all over the world who are interested in cloud computing investment, have keen insights, and are more receptive to digital assets.

Bow Miner has obtained top capital financing with its unique brand, users, and business model in the market.

Our users are those who want to improve their lives by investing in cloud mining.

Our users have their own opinions on cloud mining investment, but they also respect professionals.

Our users are investment enthusiasts who pursue self-value realization and recognition.

Bow Miner’s Innovation and Service

1. Mining requires a large amount of electricity supply. Bow Miner uses new clean energy technology to meet this challenge, reducing energy consumption through green and environmentally friendly power generation methods, and providing a more humane alternative.

2. Bow Miner’s innovative technology simplifies the mining process, and users can participate without expensive equipment or extensive technical knowledge.

3. Bow Miner lowers the investment threshold, attracts a wider audience, and promotes the wider application of cryptocurrencies.

Bow Miner’s security and reliability

Bow Miner is well aware of the importance of investor fund security and network services. Funds are safely deposited in the world’s top 10 banks (JPMorgan Chase, Barclays, HSBC, etc.). And strong security measures such as McAfee® SECURE and Cloudflare® SECURE are implemented. We are committed to transparency and legality to ensure that your investment is protected, allowing you to focus on making profits.

What services does Bow Miner provide?

1. We have 20 mining data centers around the world, including the UK, Japan, Russia, Iceland, etc.

2. We use the latest ASIC miners and GPU equipment. We have rich experience in cloud mining operations and competitive mining technology.

3. Use renewable energy to generate electricity, using the free and recyclable electricity given by nature (wind, water, solar, etc.) to provide miners with a stable power supply.

4. The data center cooling system uses various technologies to regulate and maintain the optimal temperature within the facility, which is essential to prevent equipment from overheating.

5. We know that fire prevention is essential to protect your assets. We provide comprehensive assessments designed by experts to reduce risks and improve safety standards throughout the process.

6. After 3-5 years of long-term market research and practice, we have accumulated professional cloud mining knowledge.

7. Our professional customer service team provides 24/7 online service to answer any questions you have.

8. Top technical talents from different countries around the world escort the platform to ensure the safe and normal operation of platform data and funds.

How to join Bow Miner

1. Join Bow Miner and get rewards

2. Choose your favorite contract.

3. Get your first profit.

4. Withdraw your first profits.

I cannot emphasize enough the excellent service provided by Bow Miner. The talent and dedication of their team played a major role in increasing the profitability of their contracts. Bow Miner exceeded our expectations in contract sales and was proactive and responsive – while keeping us informed every step of the way without requiring too much of our time or direct involvement. I highly recommend their contract services to any person or organization that needs real results.

Summary:

Bow Miner is the world’s leading cloud mining platform with a clear mission: to provide the tools and services you need to succeed in the digital asset space. Committed to empowering the future of finance with clean energy and providing the high-performance equipment required to achieve maximum computing power, Bow Miner promises to start your profitable cryptocurrency journey. Official website: https://88miner.com/https://88miner.com/

Media Contact

Organization: Bow Miner

Contact Person: David Barker

Website: https://88miner.com/

Email: Send Email

Contact Number: +447349569712

Address:210-212 Manchester Road Northwich CW9 7NN Cheshire United Kingdom

Address 2: Cheshire United Kingdom

City: Cheshire

State: United kindom

Country:United Kingdom

Release id:27260

Financial Disclaimer The information provided is for general informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results; all investments carry risk and you may lose the entire amount invested. Always conduct your own due diligence and consult a qualified professional before making any investment decision.

The post Bow Miner: The best free Bitcoin cloud mining platform in 2025, helping you earn daily passive income appeared first on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Cory B. George Urges People to Rethink Risk: “Calculated Chances Create Real Growth”

Published

2 hours ago

on

October 27, 2025

By

Indiana, US, 27th October 2025, ZEX PR WIRE, Real estate investor and entrepreneur Cory B. George is encouraging individuals and business owners to rethink their relationship with risk, discipline, and long-term growth. Known for managing over 100 rental properties and preparing to launch a new Midwest-based student housing investment fund, George is using his platform to highlight why measured risk-taking and emotional control are key to success in any field.

“Most people think risk is dangerous,” George said in his recent feature interview. “But avoiding it is riskier. Calculated risks create progress.”

George believes fear of uncertainty often stops people from starting businesses, investing, or chasing new goals. He’s advocating for a cultural shift—one where people embrace informed risk instead of waiting for perfect timing. “You don’t win every hand, but you learn to stay calm and wait for the right move,” he explained, drawing on lessons from his years as a poker and blackjack enthusiast.

According to the U.S. Bureau of Labor Statistics, nearly 20% of new businesses fail within the first year, largely due to poor planning or fear-based decision-making. George argues that understanding and managing risk—not avoiding it—is what separates long-term success from short-term burnout.

“Leadership isn’t about being perfect,” he said. “It’s about showing up, making decisions, and learning from what happens next. You can’t grow if you’re standing still.”

Why It Matters

George’s perspective comes as Americans face record economic uncertainty. Yet research from the Kauffman Foundation shows that entrepreneurship rates are climbing, with 500,000 new businesses started every month. His message—to take smaller, smarter risks—offers a realistic path for people seeking progress without reckless leaps.

“Start small,” George advises. “Buy one property, launch one idea, make one bold move. Test it, learn from it, then go again.”

Call to Action

Cory B. George is challenging readers to take ownership of their growth:

  • Start where you are. Don’t wait for ideal timing—learn by doing.
  • Study your mistakes. Review what worked and what didn’t.
  • Stay disciplined. Manage emotions before they manage you.

“Success isn’t about chasing everything that shines,” George said. “It’s about staying patient, taking smart chances, and trusting the process.”

To read the full interview, visit the website here.

About Cory B. George

 Cory B. George is a business leader, investor, and founder preparing to launch a real estate investment fund focused on private student housing throughout the Midwest. Since 2009, he has managed more than 100 rental properties and completed numerous single-family flips. A former General Manager at Town & Country Ford in Evansville, George is known for his disciplined, strategic approach to leadership and decision-making.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Green Bags UAE, Expands into Sustainable Promotional Gifts to Help Dubai Businesses Meet CSR Goals

Published

2 hours ago

on

October 27, 2025

By

Dubai, UAE, 27th October 2025, ZEX PR WIRE, Green Bag UAE ,a leading manufacturer of eco-friendly reusable bags, today announced the expansion of its product line to include sustainable promotional and corporate gifts for businesses across the UAE. The new collection supports Dubai companies’ growing demand for eco-conscious gifting solutions aligned with their CSR and sustainability initiatives.

With promotional gifts in Dubai playing a key role in corporate visibility, Green Bags UAE aims to bridge the gap between brand promotion and environmental responsibility. The company’s expanded offering includes customized bags including gift sets, jute bags, juco bags,cotton bags, canvas bags, custom notebooks,pens, apparels,technology gifts,drink wares and curated CSR hampers, all designed to combine utility, style, and sustainability.

Sustainability Meets Corporate Gifting

Promotional gifts are a lasting reflection of brand values,said Vipin, Marketing Manager at Green Bags UAE. “Our goal is to help Dubai businesses stand out while making a positive impact by choosing reusable,biodegradable or natural, and responsibly sourced products over single-use plastic giveaways.”

The company’s new gifting range is designed to meet the needs of corporate clients, events, and exhibitions . Each item can be customized with logos, messages, and packaging, ensuring that brands maintain a professional image while contributing to Dubai’s wider sustainability and CSR goals.Green Bags UAE supports the UAE’s Green Agenda 2030 by helping businesses adopt eco-conscious branding and reduce their environmental footprint.

Meeting Market Demand in Dubai’s Competitive Gifting Sector

In recent years, the UAE’s corporate gifting market has seen a sharp increase in demand for eco-friendly alternatives. Businesses in sectors ranging from hospitality to real estate now integrate sustainability into every aspect of their marketing ,including promotional giveaways.

By expanding its catalog, Green Bags UAE positions itself alongside the region’s leading corporate gift suppliers, offering a dedicated “Green Collection” that caters to both corporate branding and environmental stewardship.

The company leverages years of manufacturing experience, verified supplier partnerships, and transparent product sourcing to ensure each promotional gifts items custom jute,juco,cotton,canvas bags and technology gifts,apparels,note books,pens,awards,drink wares aligns with local sustainability standards.

At Green Bags UAE we specialise in promotional bags and curated eco gift sets that can be fully customised with logos, messages and packaging options.

Our core product categories:

Custom Jute & Canvas Bags   —  ideal for exhibitions, conferences and retail events.

Gift Sets                                   —   desk organisers, drinkware and sustainable tech accessories like wireless charger,speaker,power bank and bamboo tech travel kit ,charger,pen holder etc.

Eco CSR Hampers                   —  curated for Ramadan, National Day or employee appreciation programmes.

We provide sample approvals, logo mockups, and UAE-wide delivery — plus options for low-volume custom orders for trial campaigns. 

 How we design gifts that work for Dubai audiences 

 Designing an effective promotional gift is more than slapping a logo on an item. Our approach combines:

  1.   Audience fit: Corporate giveaways for exhibition visitors differ from executive hampers. We recommend lightweight reusable bags for trade shows and premium bamboo sets for executive relations.

  1.   Sustainability credentials: We source materials with clear environmental benefits (jute, organic cotton, bamboo, recycled fabrics) and provide material specs upon request. This supports CSR reporting and public procurement requirements.

  1.   Brand visibility: We optimise placement, colors and packaging to maximise logo visibility while maintaining aesthetic quality.

  1.   Logistics & speed: UAE clients need reliable, timely delivery around events and campaigns; We build production and delivery calendars that align with local event schedules .

A Greener Future for Corporate Gifting in the UAE

As Dubai strengthens its commitment to sustainable growth and responsible business practices, Green Bags UAE stands at the forefront of a new era in corporate gifting , one where creativity meets conscience. By merging aesthetic appeal, practical design, and verified eco-materials, the company empowers brands to communicate purpose through every giveaway.

With its expanded sustainable gift line, Green Bags UAE not only supports the UAE’s Green Agenda 2030 but also redefines how businesses connect with their audiences , proving that meaningful branding and environmental responsibility can go hand in hand.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

Published

6 hours ago

on

October 27, 2025

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on  27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.

 

Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.

 

The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.

 

More Information about LUCENTIS® and Ocular Neovascular Diseases

Lucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.

 

Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].

 

More Information about BEOVU® and the DME Indication

Beovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].

 

DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.

 

About NOVARTIS

Novartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. 

 

Reference:

  1. Product-related information can be found on the Novartis website at:

https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-o…

  1. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.020
  2. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 
  3. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).
  4. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.
  5. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.
  6. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.
  7. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.
  8. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.
  9. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.
  10. Chatziralli, I et al. “Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us